Welcome to our dedicated page for COGNITION THERAPEUTICS news (Ticker: CGTX), a resource for investors and traders seeking the latest updates and insights on COGNITION THERAPEUTICS stock.
Cognition Therapeutics, Inc. (NASDAQ: CGTX) is a clinical-stage biopharmaceutical company developing small molecule therapeutics for age-related degenerative disorders of the central nervous system. Its news flow centers on the clinical and regulatory progress of its lead candidate, zervimesine (CT1812), an investigational oral pill in development for Alzheimer’s disease, dementia with Lewy bodies (DLB) and related conditions.
News updates from Cognition Therapeutics frequently cover milestones in its Phase 2 clinical programs. These include results and analyses from the SHINE study in mild-to-moderate Alzheimer’s disease, the SHIMMER study in mild-to-moderate DLB, and the START study in early Alzheimer’s disease. Articles describe safety and tolerability outcomes, changes in cognition and function measured by validated scales, and exploratory findings in behavioral, movement and neuropsychiatric domains.
Investors following CGTX news also see announcements about expanded access programs for zervimesine in DLB, collaborations with organizations such as the Alzheimer’s Clinical Trials Consortium, and substantial grant support from the National Institute on Aging of the National Institutes of Health. Regulatory and scientific updates, such as end-of-Phase 2 discussions with the U.S. Food and Drug Administration, Type C meeting plans, and presentations at major Alzheimer’s disease conferences, are regular features of the company’s news cycle.
In addition, Cognition Therapeutics issues press releases on financing transactions, including registered direct offerings of common stock and at-the-market equity programs, which provide context on how it funds ongoing and planned studies. For readers tracking CGTX, this news page consolidates clinical, regulatory, scientific and capital markets developments related to zervimesine and the company’s broader neurodegenerative disease pipeline.
Cognition Therapeutics (Nasdaq: CGTX) announced that CEO Lisa Ricciardi will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026 at 3:00 p.m. ET.
Ms. Ricciardi will provide program updates on development efforts for Alzheimer's disease and dementia with Lewy bodies (DLB). A live webcast is available via the company's Investor Relations site and an archived replay will be accessible for 90 days.
Cognition Therapeutics (Nasdaq: CGTX) reported progress advancing zervimesine (CT1812) toward late‑stage development for DLB psychosis and continuing Alzheimer's programs. Key facts: $80 million fully funded Phase 2 START trial of 545 participants; START readout expected in H2 2027. SHIMMER and SHINE Phase 2 data showed strong effects, including a 95% reduction in cognitive decline for participants with low p‑tau217. Company plans FDA discussions for a registrational DLB psychosis path in Q2 2026 and will evaluate next steps after START results.
Cognition Therapeutics (Nasdaq: CGTX) reported 2025 results and clinical updates for zervimesine (CT1812). Cash and equivalents were approximately $37.0M with $35.7M in obligated NIH grant funds; company estimates runway through Q2 2027. START (545-patient) enrollment completed; SHIMMER Phase 2 showed therapeutic responses in DLB psychosis. A mid-2026 meeting with the FDA Division of Psychiatry is planned to align on a registrational plan for DLB psychosis. 2025 net loss was $23.5M (basic and diluted $(0.32)).
Cognition Therapeutics (Nasdaq: CGTX) will report fourth quarter and full-year 2025 financial results on March 26, 2026 before market open. Management will host a conference call at 8:30 a.m. ET the same day to review results and provide a business update.
The live webcast with Q&A is available via a provided link or the company's Investor Relations website; an archive and presentation will be accessible for 90 days beginning about 10:30 a.m. ET on March 26, 2026.
Cognition Therapeutics (NASDAQ: CGTX) presented Phase 2 SHIMMER data for zervimesine (CT1812) at AD/PD 2026 (March 17-21, 2026) showing an 86% slowing of decline on NPI-12 versus placebo in dementia with Lewy bodies (DLB).
The analysis showed treatment effects across neuropsychiatric, cognitive, motor, and global domains and reported directionally favorable impacts on cognitive fluctuations, memory, movement, and activities of daily living. The company said it plans development of zervimesine for DLB psychosis following a recent FDA Type C meeting.
Cognition Therapeutics (NASDAQ: CGTX) plans to advance zervimesine (CT1812) toward a registrational program for Dementia with Lewy Bodies (DLB) psychosis after receiving final FDA Type C meeting minutes following a Jan 21, 2026 meeting.
The company cites positive Phase 2 SHIMMER neuropsychiatric and motor-safety signals and expects a randomized 100mg daily vs. placebo study with an open-label extension, and a midyear 2026 FDA Division of Psychiatry meeting.
Cognition Therapeutics (NASDAQ: CGTX) extended its expanded access program (EAP) for zervimesine (CT1812) in dementia with Lewy bodies (DLB), allowing participants several additional months of treatment beyond the originally planned 12 months.
Thirty-two individuals are enrolled across eight sites, receiving 100 mg oral zervimesine daily. The company said the EAP, running since June 2025, aims to generate additional long-term safety data and reduced travel burdens by enabling local physician monitoring and local lab testing. Cognition held a Type C FDA meeting on January 21, 2026 to review SHIMMER findings; meeting minutes are expected in February.
Cognition Therapeutics (NASDAQ: CGTX) completed a Type C meeting with the U.S. Food and Drug Administration on January 21, 2026 to review plans for a proposed Phase 2b study of zervimesine (CT1812) in dementia with Lewy bodies (DLB).
The company reported the meeting was productive and that it discussed clinically meaningful endpoints for a next Phase 2b study in mild-to-moderate DLB. Cognition said it expects to receive formal meeting minutes later in the quarter and will continue dialogue with the FDA to advance clinical development in DLB, a condition with no FDA-approved therapies.
Cognition Therapeutics (NASDAQ: CGTX) published Phase 2 SHIMMER results showing that oral zervimesine (CT1812) was safe and tolerated and produced favorable effects versus placebo across behavioral, cognitive, functional and movement measures in mild-to-moderate dementia with Lewy bodies (DLB).
The randomized study enrolled 130 participants who received daily dosing for six months. Zervimesine improved neuropsychiatric inventory (NPI) scores, reduced cognitive fluctuations, and improved activities of daily living versus placebo. Most treatment-related adverse events were reported as mild or moderate. A Type C meeting with the FDA is scheduled for the second half of January 2026 to discuss next DLB studies.
Cognition Therapeutics (NASDAQ: CGTX) announced its expanded access program for zervimesine (CT1812) in dementia with Lewy bodies has reached full enrollment. Each participant will receive 100 mg oral zervimesine daily for up to one year. The program enrollment was completed in three months and was enabled by a donation from a family of a Phase 2 SHIMMER study participant.
The company has aligned with FDA on a registrational program for Alzheimer’s disease and has scheduled a Type C meeting with FDA for the second half of January to discuss a proposed Phase 3 program in DLB; meeting minutes are expected after the meeting.